Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06726265 · ClinicalTrials.gov registry record · Phase 3
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
A Phase 3 study of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by Immutep S.A.S..
- Active
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
- 20
- Study locations
NCT06726265 is a Phase 3 study of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Immutep S.A.S.. The registered enrollment target is 756 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06726265, a Phase 3 study of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Immutep S.A.S..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC). Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL eftilagimod alfa
- DRUG carboplatin plus paclitaxel
- DRUG cisplatin or carboplatin + pemetrexed
- BIOLOGICAL pembrolizumab (KEYTRUDA®)
Study Locations (20)
Other
- Centro de Endocrinologia y Diabetes Dr. Raul A. Gutman SRL - Buenos Aires
- Fundacion Respirar - Buenos Aires
- Hospital Británico de Buenos Aires - Buenos Aires
- Sanatorio Parque - Rosario - Rosario
- Clinica Viedma - Viedma
- Lyell McEwin Hospital - Elizabeth Vale
- Greenslopes Private Hospital - Greenslopes
- The Alfred Hospital - Melbourne
- Tasman Oncology Research Ltd - Southport
- St John of God Subiaco Hospital - Subiaco
- Royal Darwin Hospital - Tiwi
- Calvary Mater Newcastle - Waratah
- Cancer Care Wollongong Pty Limited - Wollongong
- Landeskrankenhaus-Universitätsklinikum Graz, KLinische Abteilung für Pulmonologie - Graz
- Vienna General Hospital - Vienna
- Antwerp University Hospital - Antwerp
- Algemeen Ziekenhuis Maria Middelares - Ghent
Kentucky
- Norton Cancer Institute - Audubon - Louisville
New Mexico
- New Mexico Oncology Hematology Consultants, Ltd. - Albuquerque
Texas
- Ascension Seton Infusion Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2029-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06726265
The ClinicalTrials.gov registry entry for NCT06726265 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immutep S.A.S., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06726265 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Kentucky, New Mexico.
Frequently Asked Questions
What is clinical trial NCT06726265 about?
NCT06726265 is a clinical study titled "Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)". The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tum...
What is the current status of trial NCT06726265?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2025-03-21. Estimated completion is 2029-09.
What conditions does trial NCT06726265 study?
This clinical trial studies the following conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06726265?
The interventions under investigation include: Placebo (OTHER), eftilagimod alfa (BIOLOGICAL), carboplatin plus paclitaxel (DRUG), cisplatin or carboplatin + pemetrexed (DRUG), pembrolizumab (KEYTRUDA®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06726265?
This trial is sponsored by Immutep S.A.S., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06726265 being conducted?
This trial has 20 study locations across Kentucky, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.